Joseph Camardo, MD, is Head of Medical Affairs at ADC Therapeutics.
Dr. Camardo has 30 years of global biopharmaceutical experience, and extensive expertise in every stage of oncology drug development.
Dr. Camardo joined ADC Therapeutics from Celgene Corporation, where he was most recently Senior Vice President of Celgene Global Health after having served as Senior Vice President of Global Medical Affairs and Corporate Medical Operations. Prior to Celgene, Dr. Camardo was Senior Vice President of Clinical Development and Medical Affairs at Forest Research Institute and spent more than 20 years at Wyeth Research before its acquisition by Pfizer. At Wyeth, he held roles including Senior Vice President of Global Medical Affairs and Senior Vice President of Clinical Research and Development. He oversaw the development of the first-ever approved antibody drug conjugate Mylotarg™ (gemtuzumab ozogamicin) for acute myeloid leukemia, among other oncology development programs.
Dr. Camardo completed medical school at the University of Pennsylvania and is board certified in internal medicine.